Anacor Pharmaceuticals, Inc.·4

Jan 21, 9:00 PM ET

Anacor Pharmaceuticals, Inc. 4

4 · Anacor Pharmaceuticals, Inc. · Filed Jan 21, 2016

Insider Transaction Report

Form 4
Period: 2016-01-19
IPPOLITO VINCENT P
EVP & Chief Commercial Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2016-01-19$19.96/sh+20,000$399,20090,985 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2016-01-1920,00061,000 total
    Exercise: $19.96Exp: 2024-03-06Common Stock (20,000 underlying)
  • Sale

    Common Stock

    2016-01-19$96.00/sh5,300$508,79771,185 total
  • Sale

    Common Stock

    2016-01-19$93.92/sh1,200$112,70489,785 total
  • Sale

    Common Stock

    2016-01-19$95.29/sh13,300$1,267,31376,485 total
  • Sale

    Common Stock

    2016-01-19$96.95/sh200$19,39070,985 total
Footnotes (6)
  • [F1]This sale was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.68 to $94.575, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.72 to $95.63, inclusive.
  • [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.78 to $96.74, inclusive.
  • [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.84 to $97.06, inclusive.
  • [F6]The award is subject to a four-year vesting period, with 25% of the shares subject to the award vesting in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting each month thereafter. The Vesting Commencement Date was February 28, 2014.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION